Navigation Links
Oral COTI-2 is effective in a second animal model of human pancreatic cancer
Date:1/20/2010

London, Ontario (January 20, 2010): Critical Outcome Technologies Inc. (COTI) (TSX Venture: COT)announced more positive results today from animal experiments carried out at a prominent Canadian cancer research facility. This new series of experiments adds to the impressive data package for COTI-2, demonstrating efficacy both as a single agent and in combination with current first line therapies, as well as low toxicity in several different animal models of human cancers.

This most recent study was designed to determine first, the effectiveness of oral COTI-2 as a single agent, second, the effectiveness of COTI-2 in combination with Abraxane, a standard first line therapy for advanced pancreatic cancer, and third, the toxicity of chronically administered oral COTI-2 as a single agent and in combination with Abraxane in an animal model of human pancreatic cancer (PANC-1). The following results provide strong evidence for the continued development of COTI-2 in combination with conventional single agent therapy for the treatment of pancreatic cancer:

  • COTI-2 is effective as a single agent in an animal model of human pancreatic cancer.

  • COTI-2 plus Abraxane was significantly more effective than Abraxane as a single agent and this result was observed by day 28 of the study.

  • The combination treatment group receiving COTI-2 plus Abraxane responded earlier than the Abraxane alone.

  • Complete tumor regressions were observed more frequently in the combination treatment groups than with single agent Abraxane.

  • At the conclusion of the study mean tumor volumes in the Abraxane only treated animals were trending higher while mean tumor volumes in the combination treatment group were trending lower.

  • Chronic oral treatment with COTI-2 as a single agent or in combination with Abraxane was well tolerated with no treatment deaths or observable toxicity over the duration of the study.

"In 2010 pancreatic cancer remains the most lethal cancer and effective oral treatments with low toxicity are urgently needed. The results of this second set of experiments confirm that chronically administered oral COTI-2 is a well tolerated effective single agent and there is enhanced efficacy in combination with Abraxane in an animal model of human pancreatic cancer," said Dr. Wayne Danter, President and CSO of COTI. "These results extend previous findings for oral COTI-2 alone and in combination with gemcitabine in pancreatic cancer. We continue to add to the impressive data set for COTI-2, showing effectiveness and low toxicity, particularly in combination with first and second line agents, against multiple cancers."

COTI will present this new data to prospective partners at BioPartnering North America taking place January 24-26, 2010 in Vancouver, Canada. "We are once again delighted with these new experimental results providing further evidence supporting the commercial potential of oral COTI-2 in pancreatic cancer," said Mr. Michael Cloutier, CEO of COTI. "This new data will stimulate further discussions as we continue to evaluate our options pertaining to a licensing arrangement for COTI-2."


'/>"/>

Contact: Michael Barr
mbarr@criticaloutcome.com
519-858-5157
Critical Outcome Technologies Inc
Source:Eurekalert

Related biology news :

1. ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER
2. Gamma globulin effective in treating eye infections caused by adenoviruses
3. UC health news: molecular pathway may predict chemotherapy effectiveness
4. Socioeconomic position associated with effectiveness of HIV drugs
5. New nanoparticle vaccine is more effective but less expensive
6. MIT model could improve some drugs effectiveness
7. Trial seeks genetic fingerprint for predicting drug effectiveness
8. New hope for horse lovers as effective control for killer ragwort is proposed
9. Quantitative PET imaging finds early determination of effectiveness of cancer treatment
10. Gene, stem cell therapy only needs to be 50 percent effective to create a healthy heart
11. Tamiflu effective for treatment and prevention of influenza in children 1 year and older
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2016)... , June 1, 2016 Favorable ... Election Administration and Criminal Identification to Boost Global Biometrics ... recently released TechSci Research report, " Global Biometrics Market ... Competition Forecast and Opportunities, 2011 - 2021", the global ... by 2021, on account of growing security concerns across ...
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the ... at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application ... team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our ...
(Date:6/23/2016)... 2016  Blueprint Bio, a company dedicated to identifying, ... community, has closed its Series A funding round, according ... "We have received a commitment from Forentis Fund ... to meet our current goals," stated Matthew Nunez ... to complete validation on the current projects in our ...
(Date:6/23/2016)... Francisco, CA (PRWEB) , ... June 23, 2016 ... ... (EDC) software, is exhibiting at the Pennsylvania Convention Center and will showcase its ... Annual conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical ...
(Date:6/23/2016)...  Amgen (NASDAQ: AMGN ) today announced ... life sciences incubator to accelerate the development of new ... at QB3@953 was created to help high-potential life science ... early stage organizations - access to laboratory infrastructure. ... two "Amgen Golden Ticket" awards, providing each winner with ...
Breaking Biology Technology: